Emyria Limited (ASX:EMD)

Emyria Limited's quarterly report for June 2026 highlights significant developments in their national clinic network expansion and positive clinical data from their depression treatment program. The company reported a revenue of approximately $1.53 million for the quarter, contributing to a full-year revenue of approximately $4.3 million, a 210% increase compared to the previous year. Emyria successfully activated its Victorian clinic and is on track to open another in Sydney by Q3 2026. The early results from their treatment-resistant depression program show significant improvements in patient outcomes, supporting the company's strategy to deliver advanced mental health treatments. Regulatory changes have broadened the clinician base eligible to deliver psychedelic-assisted psychotherapy, enhancing workforce flexibility and patient access. Emyria also launched a Global Partnership Program, creating new revenue opportunities and solidifying their position as a leader in mental health treatment delivery.